Suppr超能文献

肛管鳞状细胞癌。

Squamous cell carcinoma of the anal canal.

作者信息

Lopez M J, Myerson R J, Shapiro S J, Fleshman J W, Fry R D, Halverson J D, Kodner I J, Monafo W W

机构信息

Department of Surgery, Washington University School of Medicine, Barnes, St. Louis, Missouri 63110.

出版信息

Am J Surg. 1991 Dec;162(6):580-4. doi: 10.1016/0002-9610(91)90113-r.

Abstract

Between 1979 and 1988, 33 patients with squamous cell carcinoma of the anal canal were treated with chemoradiation. There were 24 women and 9 men, from 37 to 90 years of age (median: 63 years). Complete tumor regression occurred in 29 of the 33 patients (88%), only one of whom later developed recurrence. In the other four patients, there was persistent tumor after 3 months; three of these patients died within 2 years; and one is alive with distant metastases 2 years later. During the first 5 years of the study, seven patients with complete tumor regression underwent planned abdominoperineal resection following chemoradiation. Four of the abdominoperineal resection specimens were free of tumor, but three were not. These three patients, who had abdominoperineal resection within 3 months of chemoradiation, are disease-free. Ten of the 29 patients who had complete tumor regression had biopsies of the primary site 3 months after treatment. All biopsies were negative for residual carcinoma. At present, 26 patients (79%) are alive and disease-free from 2 to 10 years post-treatment (median: 4 years). Two patients died of unrelated causes, four of cancer, and one is alive with cancer. Complications of the chemoradiation required surgical intervention in two patients, and two others developed severe hematologic toxicity, for a complication rate of 12% (4 of 33 patients). There was no treatment-related mortality. These results support the efficacy of chemoradiation treatment for carcinoma of the anal canal. They suggest that abdominoperineal resection no longer need be part of the planned initial management, and that posttreatment biopsy of the primary site is unnecessary, unless palpable or visible abnormalities are present 3 months after treatment.

摘要

1979年至1988年间,33例肛管鳞状细胞癌患者接受了放化疗。其中女性24例,男性9例,年龄在37岁至90岁之间(中位数:63岁)。33例患者中有29例(88%)肿瘤完全消退,其中只有1例后来复发。另外4例患者在3个月后仍有持续性肿瘤;这4例患者中有3例在2年内死亡;1例在2年后出现远处转移仍存活。在研究的前5年中,7例肿瘤完全消退的患者在放化疗后接受了计划性腹会阴联合切除术。腹会阴联合切除标本中有4例无肿瘤,但3例有肿瘤。这3例在放化疗后3个月内接受腹会阴联合切除术的患者目前无病生存。29例肿瘤完全消退的患者中有10例在治疗3个月后对原发部位进行了活检。所有活检均未发现残留癌。目前,26例患者(79%)在治疗后2至10年无病生存(中位数:4年)。2例患者死于无关原因,4例死于癌症,1例患癌仍存活。放化疗的并发症导致2例患者需要手术干预,另外2例出现严重血液学毒性,并发症发生率为12%(33例患者中的4例)。无治疗相关死亡。这些结果支持放化疗治疗肛管癌的疗效。结果表明,腹会阴联合切除术不再需要作为计划性初始治疗的一部分,并且治疗后对原发部位进行活检是不必要的,除非在治疗3个月后出现可触及或可见的异常。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验